Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia
NCT04285086Phase 3Active, not recruiting
- Sponsor
- PharmaEssentia
- Start
- Aug 2020
- Primary completion
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
A Phase 3 trial of ropeginterferon alfa-2b in essential thrombocythemia (ET), sponsored by PharmaEssentia. Started Aug 2020; status: active, not recruiting.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT04285086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04285086.